NLS Pharmaceutics AG
NASDAQ:NLSP
NLS Pharmaceutics AG
NASDAQ:NLSP
Price:
0.1326 USD
-6.29%
Updated:
May 10, 2024
NLS Pharmaceutics AG
Operating Income
|
NLS Pharmaceutics AG
Operating Income Peer Comparison
Comparables:
NOVN
ROG
S
SDZ
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Operating Income
-$15.5m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Operating Income
$16.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
4%
|
|
|
Roche Holding AG
SIX:ROG
|
Operating Income
CHf18.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Operating Income
$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is NLS Pharmaceutics AG's Operating Income?
Operating Income
-15.5m
USD
-15.5m
USD
Based on the financial report for Dec 31, 2022, NLS Pharmaceutics AG's Operating Income amounts to -15.5m USD.
What is NLS Pharmaceutics AG's Operating Income growth rate?
Operating Income CAGR 5Y
-22%
-22%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for NLS Pharmaceutics AG have been -54% over the past three years , -22% over the past five years .
You don't have any saved screeners yet
